{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:51Z","timestamp":1792075551200,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Adolesc Psychiatry Ment Health"],"DOI":"10.1186\/s13034-026-01132-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:53:53Z","timestamp":1784274833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of pharmacological, adjunctive, and non-pharmacological interventions across behavioral domains in children and adolescents with autism spectrum disorder: a network meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Longyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","unstructured":"Meza N, Rees R, Escobar Liquitay CM, Franco JV, Sguassero Y, Williams K, et al. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Developmental, Psychosocial and Learning Problems Group. editor Cochrane Database Syst Reviews. 2022;2022(5). https:\/\/doi.org\/10.1002\/14651858.CD014965.","DOI":"10.1002\/14651858.CD014965"},{"issue":"1","key":"1132_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13229-022-00488-4","volume":"13","author":"S Siafis","year":"2022","unstructured":"Siafis S, \u00c7\u0131ray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, et al. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism. 2022;13(1):10. https:\/\/doi.org\/10.1186\/s13229-022-00488-4.","journal-title":"Mol Autism"},{"key":"1132_CR3","doi-asserted-by":"publisher","unstructured":"M J M. Prevalence and characteristics of autism spectrum disorder among children aged 8 years\u2014Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2020. MMWR. Surveillance Summaries, 2023, 72. MMWR Surveill Summ. 2023. https:\/\/doi.org\/10.15585\/mmwr.ss7202a1","DOI":"10.15585\/mmwr.ss7202a1"},{"issue":"1","key":"1132_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.24171\/j.phrp.2024.0286","volume":"16","author":"A Issac","year":"2025","unstructured":"Issac A, Halemani K, Shetty A, Thimmappa L, Vijay V, Koni K, et al. The global prevalence of autism spectrum disorder in children: a systematic review and meta-analysis. PHRP. 2025;16(1):3\u201327. https:\/\/doi.org\/10.24171\/j.phrp.2024.0286.","journal-title":"PHRP"},{"issue":"4","key":"1132_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ridd.2013.01.002","volume":"34","author":"JD Schmidt","year":"2013","unstructured":"Schmidt JD, Huete JM, Fodstad JC, Chin MD, Kurtz PF. An evaluation of the Aberrant Behavior Checklist for children under age 5. Res Dev Disabil. 2013;34(4):1190\u20137. https:\/\/doi.org\/10.1016\/j.ridd.2013.01.002.","journal-title":"Res Dev Disabil"},{"issue":"1","key":"1132_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10578-008-0108-7","volume":"40","author":"K Karabekiroglu","year":"2009","unstructured":"Karabekiroglu K, Aman MG. Validity of the Aberrant Behavior Checklist in a Clinical Sample of Toddlers. Child Psychiatry Hum Dev. 2009;40(1):99\u2013110. https:\/\/doi.org\/10.1007\/s10578-008-0108-7.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"9","key":"1132_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/aur.3004","volume":"16","author":"S Wang","year":"2023","unstructured":"Wang S, Chen D, Yang Y, Zhu L, Xiong X, Chen A. Effectiveness of physical activity interventions for core symptoms of autism spectrum disorder: A systematic review and meta-analysis. Autism Res. 2023;16(9):1811\u201324. https:\/\/doi.org\/10.1002\/aur.3004.","journal-title":"Autism Res"},{"issue":"4","key":"1132_CR8","doi-asserted-by":"publisher","first-page":"E299","DOI":"10.1503\/jpn.210191","volume":"47","author":"SC Liang","year":"2022","unstructured":"Liang SC, Sun CK, Fan HY, Chung W, Tzang RF, Hung KC, et al. Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-analysis. J Psychiatry Neurosci. 2022;47(4):E299\u2013310. https:\/\/doi.org\/10.1503\/jpn.210191.","journal-title":"J Psychiatry Neurosci"},{"issue":"6","key":"1132_CR9","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1003","volume":"7","author":"S Deb","year":"2021","unstructured":"Deb S, Roy M, Lee R, Majid M, Limbu B, Santambrogio J, et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open. 2021;7(6):e179. https:\/\/doi.org\/10.1192\/bjo.2021.1003.","journal-title":"BJPsych Open"},{"issue":"2","key":"1132_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/13623613221119368","volume":"27","author":"D Trembath","year":"2023","unstructured":"Trembath D, Varcin K, Waddington H, Sulek R, Bent C, Ashburner J, et al. Non-pharmacological interventions for autistic children: an umbrella review. Autism. 2023;27(2):275\u201395. https:\/\/doi.org\/10.1177\/13623613221119368.","journal-title":"Autism"},{"key":"1132_CR11","doi-asserted-by":"publisher","unstructured":"Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Developmental, Psychosocial and Learning Problems Group. editor Cochrane Database Syst Reviews. 2016;2016(6). https:\/\/doi.org\/10.1002\/14651858.CD009043.pub3.","DOI":"10.1002\/14651858.CD009043.pub3"},{"issue":"11","key":"1132_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139. https:\/\/doi.org\/10.1097\/CHI.0b013e3181b76658.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1132_CR13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230256","author":"E Leibenluft","year":"2024","unstructured":"Leibenluft E, Carlson GA, Kircanski K, Perlman SB, Silver J, Wakschlag LS. Irritability in youths: a critical integrative review. Am J\u00a0Psychiatry. 2024. https:\/\/doi.org\/10.1176\/appi.ajp.20230256.","journal-title":"Am J\u00a0Psychiatry"},{"issue":"6","key":"1132_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/cap.2015.0005","volume":"25","author":"M Aman","year":"2015","unstructured":"Aman M, Rettiganti M, Nagaraja HN, Hollway JA, McCracken J, McDougle CJ, et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. J Child Adolesc Psychopharmacol. 2015;25(6):482\u201393. https:\/\/doi.org\/10.1089\/cap.2015.0005.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1132_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1660040","volume":"16","author":"X Fu","year":"2025","unstructured":"Fu X, Shi P. The intervention effect of structured martial arts games on behavioral impairments and motor functions in children with autism spectrum disorder. Front Psychol. 2025;16:1660040. https:\/\/doi.org\/10.3389\/fpsyg.2025.1660040.","journal-title":"Front Psychol"},{"issue":"3","key":"1132_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/cap.2018.0115","volume":"29","author":"MS Fallah","year":"2019","unstructured":"Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019;29(3):168\u201380. https:\/\/doi.org\/10.1089\/cap.2018.0115.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"1132_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Newark: John Wiley & Sons, Incorporated; 2019. p. 1.","edition":"2"},{"issue":"2","key":"1132_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple\u2010treatments meta\u2010analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synthesis Methods. 2012;3(2):80\u201397. https:\/\/doi.org\/10.1002\/jrsm.1037.","journal-title":"Res Synthesis Methods"},{"issue":"10","key":"1132_CR20","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. B <>Haibe-Kains editor 2013 Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE 8 10 e76654 https:\/\/doi.org\/10.1371\/journal.pone.0076654.","journal-title":"PLoS ONE"},{"key":"1132_CR21","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39:e2017047. https:\/\/doi.org\/10.4178\/epih.e2017047.","journal-title":"Epidemiol Health"},{"issue":"2","key":"1132_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"key":"1132_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017. https:\/\/doi.org\/10.1186\/s13643-017-0473-z.","journal-title":"Syst Rev"},{"issue":"4","key":"1132_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1542\/peds.2013-1546","volume":"132","author":"V Chirdkiatgumchai","year":"1994","unstructured":"Chirdkiatgumchai V, Xiao H, Fredstrom BK, Adams RE, Epstein JN, Shah SS, et al. National trends in psychotropic medication use in young children: 1994\u20132009. Pediatrics. 1994;132(4):615\u201323. https:\/\/doi.org\/10.1542\/peds.2013-1546.","journal-title":"Pediatrics"},{"issue":"10","key":"1132_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/cap.2019.0018","volume":"29","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Stewart DG, Chan P, Tehrani A, Patten SB. The pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016. J Child Adolesc Psychopharmacol. 2019;29(10):740\u20135. https:\/\/doi.org\/10.1089\/cap.2019.0018.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"1132_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.chc.2009.02.005","volume":"18","author":"J Fanton","year":"2009","unstructured":"Fanton J, Gleason MM. Psychopharmacology and preschoolers: a critical review of current conditions. Child Adolesc Psychiatr Clin N Am. 2009;18(3):753\u201371. https:\/\/doi.org\/10.1016\/j.chc.2009.02.005.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"12","key":"1132_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/chi.0b013e3181570d9e","volume":"46","author":"MM Gleason","year":"2007","unstructured":"Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1532\u201372. https:\/\/doi.org\/10.1097\/chi.0b013e3181570d9e.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"1132_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/cap.2006.16.575","volume":"16","author":"J Luby","year":"2006","unstructured":"Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575\u201387. https:\/\/doi.org\/10.1089\/cap.2006.16.575.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"1132_CR29","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.euroneuro.2015.06.009","volume":"25","author":"AM Persico","year":"2015","unstructured":"Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, et al. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur Neuropsychopharmacol. 2015;25(10):1513\u201331. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.009.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"1132_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/children8050318","volume":"8","author":"HA Alsayouf","year":"2021","unstructured":"Alsayouf HA, Talo H, Biddappa ML, De Los Reyes E. Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: case study. Children (Basel). 2021;8(5):318. https:\/\/doi.org\/10.3390\/children8050318.","journal-title":"Children (Basel)"},{"issue":"4","key":"1132_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/cap.1999.9.273","volume":"9","author":"DJ Posey","year":"1999","unstructured":"Posey DJ, Walsh KH, Wilson GA, McDOUGLE CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999;9(4):273\u20136. https:\/\/doi.org\/10.1089\/cap.1999.9.273.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"1132_CR32","first-page":"33","volume":"8","author":"A Fayyazi","year":"2014","unstructured":"Fayyazi A, Salari E, Khajeh A, Gajarpour A. A comparison of risperidone and buspirone for treatment of behavior disorders in children with phenylketonuria. Iran J Child Neurol. 2014;8(4):33\u20138.","journal-title":"Iran J Child Neurol"},{"key":"1132_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002. https:\/\/doi.org\/10.1056\/NEJMoa013171.","journal-title":"N Engl J Med"},{"key":"1132_CR34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45524","author":"J Hutchinson","year":"2023","unstructured":"Hutchinson J, Folawemi O, Bittla P, Kaur S, Sojitra V, Zahra A, et al. The effects of risperidone on cognition in people with autism spectrum disorder: a systematic review. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.45524.","journal-title":"Cureus"},{"key":"1132_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.1078983","volume":"16","author":"BD Alvarez","year":"2022","unstructured":"Alvarez BD, Cavazos C, Morales CA, M. Lopez S, Amodeo DA. Impact of specific serotonin receptor modulation on restricted repetitive behaviors. Front Behav Neurosci. 2022;16:1078983. https:\/\/doi.org\/10.3389\/fnbeh.2022.1078983.","journal-title":"Front Behav Neurosci"},{"key":"1132_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.787097","volume":"12","author":"V Mandic-Maravic","year":"2022","unstructured":"Mandic-Maravic V, Grujicic R, Milutinovic L, Munjiza-Jovanovic A, Pejovic-Milovancevic M. Dopamine in autism spectrum disorders\u2014focus on D2\/D3 partial agonists and their possible use in treatment. Front Psychiatry. 2022;12:787097. https:\/\/doi.org\/10.3389\/fpsyt.2021.787097.","journal-title":"Front Psychiatry"},{"key":"1132_CR37","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/NDT.S151802","volume":"14","author":"N Maneeton","year":"2018","unstructured":"Maneeton N, Maneeton B, Puthisri S, Woottiluk P, Narkpongphun A, Srisurapanont M. Risperidone for children and adolescents with autism spectrum disorder: a systematic review. NDT. 2018;14:1811\u201320. https:\/\/doi.org\/10.2147\/NDT.S151802.","journal-title":"NDT"},{"issue":"4","key":"1132_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2174\/1570159X18666200529151741","volume":"19","author":"BJ Mano-Sousa","year":"2021","unstructured":"Mano-Sousa BJ, Pedrosa AM, Alves BC, Galdur\u00f3z JCF, Belo VS, Chaves VE, et al. Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis. CN. 2021;19(4):538\u201352. https:\/\/doi.org\/10.2174\/1570159X18666200529151741.","journal-title":"CN"},{"key":"1132_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1027799","volume":"13","author":"CVA Toscano","year":"2022","unstructured":"Toscano CVA, Ferreira JP, Quinaud RT, Silva KMN, Carvalho HM, Gaspar JM. Exercise improves the social and behavioral skills of children and adolescent with autism spectrum disorders. Front Psychiatry. 2022;13:1027799. https:\/\/doi.org\/10.3389\/fpsyt.2022.1027799.","journal-title":"Front Psychiatry"},{"issue":"2","key":"1132_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/antiox11020350","volume":"11","author":"M Daniela","year":"2022","unstructured":"Daniela M, Catalina L, Ilie O, Paula M, Daniel-Andrei I, Ioana B. Effects of Exercise Training on the Autonomic Nervous System with a Focus on Anti-Inflammatory and Antioxidants Effects. Antioxidants. 2022;11(2):350. https:\/\/doi.org\/10.3390\/antiox11020350.","journal-title":"Antioxidants"},{"key":"1132_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105336","volume":"131","author":"A Caplin","year":"2021","unstructured":"Caplin A, Chen FS, Beauchamp MR, Puterman E. The effects of exercise intensity on the cortisol response to a subsequent acute psychosocial stressor. Psychoneuroendocrinology. 2021;131:105336. https:\/\/doi.org\/10.1016\/j.psyneuen.2021.105336.","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"1132_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2544","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhou H, Luo Q, Cui S. The effect of physical exercise on circulating brain-derived neurotrophic factor in healthy subjects: a meta\u2010analysis of randomized controlled trials. Brain Behav. 2022;12(4):e2544. https:\/\/doi.org\/10.1002\/brb3.2544.","journal-title":"Brain Behav"},{"issue":"7","key":"1132_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcn.13016","volume":"74","author":"S Momtazmanesh","year":"2020","unstructured":"Momtazmanesh S, Amirimoghaddam-Yazdi Z, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double\u2010blind, placebo\u2010controlled clinical trial. Psychiatry Clin Neurosci. 2020;74(7):398\u2013405. https:\/\/doi.org\/10.1111\/pcn.13016.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"12","key":"1132_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13123025","volume":"13","author":"E Sclabassi","year":"2025","unstructured":"Sclabassi E, Peret S, Qian C, Gao Y. Pharmacological interventions in autism spectrum disorder: a comprehensive review of mechanisms and efficacy. Biomedicines. 2025;13(12):3025. https:\/\/doi.org\/10.3390\/biomedicines13123025.","journal-title":"Biomedicines"},{"issue":"3","key":"1132_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40263-023-00993-x","volume":"37","author":"G Arteaga-Henr\u00edquez","year":"2023","unstructured":"Arteaga-Henr\u00edquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and\/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: a narrative review of randomized, placebo-controlled trials. CNS Drugs. 2023;37(3):215\u201329. https:\/\/doi.org\/10.1007\/s40263-023-00993-x.","journal-title":"CNS Drugs"},{"key":"1132_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00849","volume":"10","author":"S Hafizi","year":"2019","unstructured":"Hafizi S, Tabatabaei D, Lai MC. Review of clinical studies targeting inflammatory pathways for individuals with autism. Front Psychiatry. 2019;10:849. https:\/\/doi.org\/10.3389\/fpsyt.2019.00849.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1132_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bmjebm-2021-111804","volume":"28","author":"C Fieiras","year":"2023","unstructured":"Fieiras C, Chen MH, Escobar Liquitay CM, Meza N, Rojas V, Franco JVA, et al. Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews. BMJ EBM. 2023;28(1):7\u201314. https:\/\/doi.org\/10.1136\/bmjebm-2021-111804.","journal-title":"BMJ EBM"}],"container-title":["Child and Adolescent Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-026-01132-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:03:32Z","timestamp":1792073012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-026-01132-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1186\/s13034-026-01132-2","relation":{},"ISSN":["1753-2000"],"issn-type":[{"value":"1753-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this study was based on previously published data, no ethical approval or informed consent was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}